Introduction
Empyema is defined as pus in the pleural space. 1 Pus is thick,
viscid fluid that appears to be purulent. Empyema typically is a complication of pneumonia and can arise from other rare causes. The occurrence of empyema varies depending on microorganisms, community-or hospital-acquired infection, the age and gender of the patients and host immune status. 2 Several risk factors have been identified including alcoholism, intravenous drug use, diabetes, immunocompromised status, neoplasm and pre-existent pulmonary disease or pleural effusion. 2, 3 Patients with empyema and comorbid chronic illness portend a poorer prognosis and a higher mortality. 4 Patients with end-stage renal disease (ESRD) are at a higher risk of acquiring various types of infections. Infection is the second leading cause of death following cardiovascular diseases in patients with ESRD. 5 The mechanisms through which ESRD predisposes patients to infection include alterations of host defense, advanced age, presence of comorbid conditions, invasive dialysis procedures, disruption of skin and mucosal barriers, malnutrition and susceptibility to nosocomial transmission. 6 Evidence has also shown that patients with ESRD have a significantly higher risk for pulmonary infections. 7, 8 Some studies have described the association between chronic kidney disease (CKD) and empyema. Smith et al. have reported their 14-year experience that systemic illness was a risk factor in 29/102 (28.4%) cases with empyema, including diabetes, alcoholism, malignancy, rheumatic diseases, CKD and malnutrition. 9 We have previously analyzed 633 cases of empyema admitted to China Medical University Hospital (CMUH) during 2001-2006. Among these patients, there were 84 cases (13.3%) with stage 4 CKD and 40 cases (6.32%) with ESRD. 10 In another retrospective study in Taiwan, Chen et al. enrolled 602 adult patients with acute bacterial empyema and they observed that there were 65 patients (10.8%) with CKD. 11 However, the precise incidence of empyema in patients with ESRD and the risk of empyema for patients with ESRD compared to the general population are largely unknown. The National Health Insurance Research Database (NHIRD) in Taiwan is a nationwide database that contains cohort data for 23 million people. These reliable data have been used for various studies, including studies on ESRD and empyema. [12] [13] [14] [15] The hypothesis of this study is that patients with ESRD have an increased likelihood of subsequent occurrence of empyema. The aim of this study was to investigate the risk of incident empyema in patients with ESRD and compare it with the general population.
Materials and methods

Data source
The Taiwan government established the Taiwan National Health Insurance (TW-NHI) program in March 1995, which is a single-payer and a compulsory insurance system for >99% of 23.74 million Taiwan residents. The NHIRD is a claims database from the NHI program. We used the scrambled identification of residents to link three data files that included the Registry for Catastrophic Illness Patient Database (RCIPD), Registry of Beneficiaries (RB) and inpatient claims. These data files record diseases based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). This study was evaluated and approved by the Research Ethics Committee of China Medical University and Hospital (CMUH-104-REC2-115).
Sampled participants
This study was focused on the risk of empyema between patients with ESRD and individuals without kidney disease. The ESRD cohort included newly diagnosed ESRD adults (ICD-9-CM 585.6) within the RCIPD from January 1, 2000, to December 31, 2008. The date of ESRD diagnosis was defined as the index date. We excluded patients with a history of empyema (ICD-9-CM code 510) before the index date. The comparison cohort included individuals without kidney disease within the RB identified during the same period of 2000-2008, with the same exclusion criteria as in the ESRD cohort. Individuals in the ESRD and the comparison cohorts were selected by 1:1 matching based on a propensity score. The score was calculated using a logistic regression model to estimate the probability of disease assignment, based on the baseline variables including age, gender, index year and comorbidities of diabetes (ICD-9-CM code 250), asthma (ICD-9-CM code 493), chronic obstructive pulmonary disease (COPD) (ICD-9-CM code 496), chronic liver disease and cirrhosis (CLD) (ICD-9-CM code 571), cancer (ICD-9-CM codes 140 À 208), systemic lupus erythematosus (SLE)/rheumatoid arthritis (RA)/immune disorders (ICD-9-CM codes 710.0, 714.0, 279), organ transplant (ICD-9-CM code V42), malnutrition (ICD-9-CM codes 260 À 269) and obesity (ICD-9-CM code 278.0). All the individuals were followed up from the index date to the date of empyema diagnosis, withdrawal from the NHI program, or the end of 2011, whichever came first.
Statistical analysis
The distribution of age, gender and comorbidities was expressed as frequency (percentage) or mean 6 standard deviation (SD). Baseline characteristics of both the ESRD and comparison cohorts were compared using standardized mean differences. Values of standardized mean differences 0.01 indicated a negligible difference in mean values between the ESRD and comparison cohorts. Cumulative incidence curves for empyema were plotted using the Kaplan-Meier method and the differences in curves between the ESRD and comparison cohorts were tested using a log-rank test. The incidences of pneumonia (ICD-9-CM code 486) or empyema in the ESRD and comparison cohorts were calculated by dividing the total number of pneumonia or empyema events by the total follow-up period (per 10 000 person-years). Univariable and multivariable Cox proportional hazards model were used to measure the effect of ESRD on the time to empyema development. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were estimated by Cox regression. Only significant values in the univariable model were further examined in the multivariable model. For further data analysis, we assessed the effects of different dialysis modalities on the risk for empyema. In addition, logistic regression analysis was used to measure the odds ratio (OR) of 30-day mortality since the diagnosis of empyema between the two groups. All statistical analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA) for Windows. The level of significance was set at 0.05 using a two-tailed test.
Results
We included 82 765 patients in the ESRD cohort and 82 765 individuals in the comparison cohort and the distributions of age, gender and comorbidities between both the cohorts were similar ( Table 1 ). The mean ages in the ESRD cohort and the comparison cohort were 62.7 6 14.2 years and 62.5 6 14.4 years, respectively. In both the cohorts, 48.3% of patients were aged ! 65 years and 50.9% of the patients were women. The major comorbidity was diabetes (52.4%) in both cohorts, followed by COPD (10.9 vs. 11.0%), CLD (both 10.6%), cancer (6.39 vs. 6.41%) and asthma (4.40 vs. 4.41%).
There were 832 and 412 incident empyema events and 4.24 6 3.19 years and 6.08 6 3.01 years of mean follow-up in the ESRD and comparison cohorts, respectively ( Table 2 ). Figure 1 shows the cumulative incidence of empyema curves and reveals that the curve for patients with ESRD was significantly higher than the curve for the comparison cohort. Overall, the incidence density rates of empyema were 23.7 and 8.19 per 10 000 person-years for the ESRD and comparison cohorts. After adjusting for age, gender and comorbidities of diabetes, COPD, CLD and malnutrition, patients with ESRD showed a 3.01-fold higher risk of developing empyema than the comparison cohort [adjusted HR (aHR) ¼ 3.01, 95% CI ¼ 2.67-3.39]. In addition, we measured the incidence of pneumonia was 2.46-fold higher in the ESRD group than in the comparison group (486.0 vs. 193.9/ 10 000 person-years, P < 0.001), with a similar adjusted HR of 3.01 (95% CI ¼ 2.93-3.10) in the same settings.
Compared with patients aged 20-49 years, the risk of empyema was 1.24-fold higher in those aged 50-64 years (95% CI ¼ Figure 2 shows the comparison of empyema incidence and HRs measured using the Cox model between patients with ESRD and comparison individuals after stratification by gender, age and comorbidity. The incidence of empyema was higher in men than in women and increased with age and comorbidity. The ESRD cohort to the comparison cohort aHRs of empyema were all significant. Further, we analyzed the incidence and HR of empyema by different dialysis modalities (Table 3) 
Discussion
To the best of our knowledge, this is the first nationwide, propensity-matched cohort study to evaluate incident empyema in patients with ESRD. In the present study, we found that there was a significant risk of empyema in patients with ESRD compared with those without kidney disease. The aHRs of empyema for the ESRD group compared with the comparison group after stratification by gender, age and comorbidity were all significant. Furthermore, the incidences of empyema were higher in men than in women, in older people than in young people and in individuals with comorbidity than in those without comorbidity. These findings are in accordance with the current concepts. In addition, the incidence of empyema was without difference between ESRD patients undergoing HD and PD. Moreover, we found that 30-day mortality rate since diagnosis of empyema was significantly higher in ESRD group than the comparison group.
The association between ESRD and empyema remains largely uncertain. First, patients with ESRD are at a higher risk of acquiring various types of infections, including pneumonia. Pneumonia in patients with ESRD undergoing dialysis has been defined as a specific type of pneumonia, health-care-associated pneumonia (HCAP), of which the clinical and microbiological features are more similar to those of hospital-acquired pneumonia. 16, 17 That is, the pathogens of HCAP are often multidrug-resistant bacteria, which is a risk factor for developing empyema. Second, patients with ESRD commonly present with pleural effusion. This condition frequently arises from fluid overload, nephrotic syndrome, uremic pleurisy, or pleuro-renal syndrome. 18 In a cross-sectional study in India, Ray et al. have reported that pleural effusion was found in 29 out of 430 patients (6.7%) with CKD. 19 Even if the effusion is often transudate in original, it is possible to become infected and exudate when the individual gets a pneumonia or certain infection. It is also possible that the effusion finally leads to empyema development. Another important concern is immunosuppression. ESRD is well known to be associated with immunocompromised status [20] [21] [22] , which might play an essential role in empyema development. Therefore, it is not surprising that the 30-day mortality since empyema diagnosis in patients with ESRD has been reported significantly higher than those without kidney disease in the present study. 10 Dialysis modality is associated with the occurrence of different types of infections. It is well known that patients undergoing HD have a higher risk of bacteremia and those undergoing PD have a high risk of peritonitis. 23 A review of the US Renal Data System (USRDS) indicated that the overall incidence rates of pneumonia were 29.0/100 person-years in patients undergoing HD and 18.2/100 person-years in those undergoing PD (P < 0.0001). 24 In another Canadian study during 2001-2007, 49/354 (13.8%) patients undergoing HD and 19/354 (5.4%) patients undergoing PD were identified to have pneumonia-related hospitalization. 25 Since empyema is most closely associated with pneumonia, incident empyema may be higher in patients undergoing HD than in those undergoing PD. However, in the present study, we found that the incidence of empyema was without difference between HD and PD. The strength of this study is that we performed a nationwide, propensity-matched evaluation of patients with ESRD and we assessed their risk of developing empyema. It is expensive to conduct a prospective cohort study; thus, a retrospective cohort study using insurance data is a suitable and economical alternative. The NHI program has covered >99.5% of Taiwanese population since 2010. Universal coverage reduces barriers to health care access for all citizens, regardless of socioeconomic background and/or residential location. 26 In the present study, by using NHIRD, we were able to reflect a "real world" scenario wherein ESRD, empyema and all comorbidities were directly diagnosed during a medical consultation.
There were several limitations that should be considered when interpreting the results of the present study. First, the ICD-9-CM algorithm was used to define ESRD, empyema and comorbidities; thus, the diagnosis of ESRD is most accurate because it required a carefully peer-reviewed process in order to confirm it as a catastrophic illness. All the other diagnoses depended on the competence of clinical physicians. An ad hoc committee established by the insurance authority was in charge *P < 0.05, **P < 0.01, ***P < 0.001.
of evaluating the claims data to prevent errors and violations. In addition, we selected only those diagnoses that appeared at least twice within a year to increase the validity and accuracy. Second, the NHIRD does not provide detailed information about the etiology of ESRD, family history, environmental factors and smoking or drinking habits, which may have been potentially confounding factors in the present study. In addition, relevant clinical variables such as serum laboratory data, image reports and culture results were not available in our study. 27 
Conclusion
The risk of empyema was significantly higher in patients with ESRD than in those without kidney disease. The occurrence of empyema was without difference in patients undergoing HD compared to those undergoing PD. The 30-day mortality rate Figure 2 . Gender-, age-and comorbidity-specific ESRD to non-ESRD hazard ratios of empyema. b Multivariable analysis including age, gender and comorbidities of diabetes, asthma, and COPD.
*P < 0.05, **P < 0.01, ***P < 0.001. since empyema diagnosis was also significantly higher in patients with ESRD than those without kidney disease.
